We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Perrigo Company (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration and has launched an AB rated generic version of Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1%/2.5%.